ACE2 News and Research

RSS

Remdesivir prevents replication of SARS-CoV-2 in human intestinal organoids

A new German study published on the preprint server bioRxiv* in June 2020 shows that the drug remdesivir can reduce the replication of SARS-CoV-2 in human intestinal organoids.

14 Jun 2020

Effect of human genes on severity and infectivity of SARS-CoV-2

Now, a new paper published on the preprint server medRxiv* reports the results of an analysis of the association between the genetic variants in the patients and the clinical progression of the disease. The study included 332 patients hospitalized with COVID-19 in a single-center, with widely varying laboratory and clinical features. There were 25, 12, and 17 patients with asymptomatic, mild, and critical disease.

14 Jun 2020

An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response

Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.

14 Jun 2020

WVU researchers develop new diagnostic and antibody tests for COVID-19

COVID-19 tests are in short supply. The companies that make the necessary chemicals--called reagents--can't keep up with demand. But researchers at West Virginia University are developing new tests on their own to identify who has COVID-19 now and who had it in the past but recovered.

11 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

Race-related differences in genetic determinants of COVID-19 severity

Researchers at the University of Iowa have identified differences in gene expression levels between African Americans and European Americans that may explain the disproportionately higher rates of coronavirus disease 2019 (COVID-19) cases and related deaths among African Americans.

11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

COVID-19 mouse model could accelerate the search for treatments, vaccines

The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

Twist Bioscience and Serimmune collaborate to identify SARS-CoV-2 therapeutic antibody candidates

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Serimmune Inc., a leader in understanding the functional antibody repertoire’s role in human disease, today announced a collaboration to identify and evaluate SARS-CoV-2 therapeutic antibody candidates from Twist libraries.

From Twist Bioscience 10 Jun 2020

Unique mutations could weaken Indian SARS-CoV-2 strain

A new study published on the preprint server bioRxiv in June 2020 suggests that the presence of unique mutations in the viral strains circulating in India has led to their attenuation.

9 Jun 2020

Examining the effect of smoking, nicotine and vaping on COVID-19 severity

Researchers at the University of Oxford say they will be conducting the most extensive study to date linking primary and clinical data for the assessment of associations between smoking status and the severity of coronavirus disease 2019 (COVID-19).

9 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

COVID-19 produces lung inflammation in non-human primate experiments

A new study published on the online preprint server bioRxiv in June 2020 reports the successful use of three primate species to model the infection, pathogenesis, and clinical features associated with COVID-19. The research provides useful and immediately available models to test new vaccines and treatments.

9 Jun 2020

Metabolic diseases alter ACE2 expression and increase COVID-19 severity

A new study published on the preprint server medRxiv in June 2020 reports that one mechanism for this variable severity is the differential expression of the ACE2 receptor in various metabolic conditions, thereby facilitating viral entry into the host cells.

9 Jun 2020

New study shows possible alternative pathway of SARS-CoV-2 infection in overactive bladder

A new study published on the preprint server bioRxiv*, in June 2020, reports that the condition of overactive bladder (OAB) could be associated with a different route of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19 disease.

8 Jun 2020

Indirect viral infection of the kidneys by SARS-CoV-2-induced inflammatory reaction

SARS-CoV-2-associated acute kidney injury is not uncommon. Many hospitalized COVID-19 patients - as many as 80% of critically ill COVID-19 patients, according to a current study - develop acute kidney injury, but without requiring dialysis in most cases. Proteinuria and hematuria are present in about half the cases.

8 Jun 2020

Census of viral spike protein antigens could benefit development of SARS-CoV-2 therapeutics

A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.

8 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

SARS-CoV-2 infection causes specific kidney proximal tubular injury

SARS-CoV-2-associated acute kidney injury (AKI) is one of the more frequently encountered organ involvements in COVID-19 - in as many as 80% of critically ill patients, according to a recent study.

8 Jun 2020